Sequential Targeting of PARP with Carboplatin Inhibits Primary Tumor Growth and Distant Metastasis in Triple-Negative Breast Cancer

Researchers evaluated the impact of the concurrent combination of talazoparib and carboplatin on cell survival in 13 TNBC cell lines. They compared the concurrent and sequential combination upon fork replication, migration, and invasion.